MedTrace Logo

Retrospective Evaluation of CML Patients in the National Compassionate Program

NCT02448095 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2022-10-26

No results posted yet for this study

Summary

This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.

Conditions

  • Chronic Myeloid Leukemia
  • Philadelphia Positive

Interventions

DRUG

Ponatinib

Observation of tolerability and safety profiles

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Carmen Fava · Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 - Orbassano

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-22
Primary Completion
2018-07-17
Completion
2018-07-17

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448095 on ClinicalTrials.gov